我們已在上線! 進一步了解
HGEN

Humanigen

已下市

HGEN已於2023年7月25日下市。

 

公司簡介: Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.

員工: 6

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於HGEN的最新新聞文章。

價格圖表採用Lightweight Charts™實作